Xu Xiaolin, Mao Xueting, Liu Bo, Sun Yixin, Cheng Xiaoling, Wang Xiaoling, Mao Huawei
Department of Immunology, Beijing Children's Hospital, Capital Medical University, Beijing, 100045, China.
Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, 100045, China.
Drugs R D. 2025 Mar;25(1):79-88. doi: 10.1007/s40268-025-00506-9. Epub 2025 Apr 11.
The purpose of this study is to investigate the status of blood concentration of sirolimus (SRL), explore the factors influencing SRL drug blood concentration, and provide guidance for the appropriate utilization of clinical medications.
A single-center retrospective cohort study encompassed 1535 blood drug concentration observations obtained from 249 children from August 2018 to June 2023. Participants were categorized into four groups (A, B, C, and D) on the basis of their blood concentration levels at various time intervals. The analysis focused on identifying the factors that influenced blood concentration in the short- and long-term posttreatment. The primary endpoint was factors affecting the sirolimus blood concentration. The effect of physiopathological indicators on the corrected blood drug concentration (C/D value) was analyzed to avoid the effect of differences in the dose of SRL used in patients on SRL blood concentrations. The multiple linear regression model was used to examine the impact of factors influencing pharmacokinetics and pharmacodynamics on the C/D.
Analysis of SRL blood concentration monitoring indicated that a majority (60.43%) of patients demonstrated a trough sirolimus concentration (C) below the level of the recommended threshold of 5 ng/mL, while approximately 17.7% of patients exceeded 15 ng/mL. The results indicated a noteworthy association between weight and body surface area (BSA) and the C/D of SRL in groups A, B, and D (P < 0.05). Additionally, aspartate transaminase (AST), alanine aminotransferase (ALT), and albumin (ALB) in group A; ALB in group B; and platelet count (PLT) in group C demonstrated a statistically significant correlation with the C/D of SRL (P < 0.05).
Clinicians should optimize medication plans by considering the child's weight, BSA, ALT, AST, PLT, ALB, and relevant factors. These findings may serve as a valuable resource for clinicians.
本研究旨在调查西罗莫司(SRL)的血药浓度状况,探究影响SRL药物血药浓度的因素,为临床合理用药提供指导。
一项单中心回顾性队列研究纳入了2018年8月至2023年6月期间从249名儿童中获取的1535次血药浓度观察数据。参与者根据其在不同时间间隔的血药浓度水平分为四组(A、B、C和D组)。分析重点在于确定治疗后短期和长期影响血药浓度的因素。主要终点是影响西罗莫司血药浓度的因素。分析生理病理指标对校正血药浓度(C/D值)的影响,以避免患者使用的SRL剂量差异对SRL血药浓度的影响。采用多元线性回归模型研究影响药代动力学和药效学的因素对C/D的影响。
SRL血药浓度监测分析表明,大多数(60.43%)患者的西罗莫司谷浓度(C)低于推荐阈值5 ng/mL,而约17.7%的患者超过15 ng/mL。结果表明,A、B和D组的体重、体表面积(BSA)与SRL的C/D之间存在显著关联(P < 0.05)。此外,A组的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和白蛋白(ALB);B组的ALB;以及C组的血小板计数(PLT)与SRL的C/D具有统计学显著相关性(P < 0.05)。
临床医生应通过考虑儿童的体重、BSA、ALT、AST、PLT、ALB及相关因素来优化用药方案。这些发现可为临床医生提供有价值的参考。